PRO-140: Humanized anti-CCR5 monoclonal antibody anti-HIV agent

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


PRO-140 is a humanized anti-CCR5 monoclonal antibody currently in phase II clinical development for the treatment of HIV. It has exhibited potent in vitro antiviral activity against a broad range of HIV-1 isolates. This antiviral activity has been confirmed in a number of clinical studies involving HIV-infected patients, with no drug-related serious adverse events reported.

Original languageEnglish (US)
Pages (from-to)789-792
Number of pages4
JournalDrugs of the Future
Issue number10
StatePublished - 2009

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'PRO-140: Humanized anti-CCR5 monoclonal antibody anti-HIV agent'. Together they form a unique fingerprint.

Cite this